Peter Johnson

Peter Johnson

Auto-generated profile, based on publicly available information

Peter Johnson

Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4Rz, U.K.

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
DBDaniele Bertoglio
Daniele Bertoglio
JBJonathan Bard
Jonathan Bard
MHManuela Hessmann
Manuela Hessmann
LLLongbin Liu
Longbin Liu
AGAnnette Gärtner
Annette Gärtner
IMIgnacio Muñoz-Sanjuán
Ignacio Muñoz-Sanjuán
Huntington’s disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG trinucleotide expansion in the huntingtin ( HTT ) gene that encodes the pathologic mutant HTT (mHTT) protein with an expanded polyglutamine (polyQ) tract. Whereas several therapeutic programs targeting mHTT expression have advanced to clinical evaluation, methods to visualize mHTT protein species in the living brain are lacking. Here, we demonstrate the development and characterization of a positron emission tomography (PET) imaging radioligand with high affinity and selectivity for mHTT aggregates. This small molecule radiolabeled with 11 C ([ 11 C]CHDI-180R) allowed noninvasive monitoring of mHTT pathology in the brain and could track region- and time-dependent suppression of mHTT in response to therapeutic interventions targeting mHTT expression in a rodent model. We further showed that in these animals, therapeutic agents that lowered mHTT in the striatum had a functional restorative effect that could be measured by preservation of striatal imaging markers, enabling a translational path to assess the functional effect of mHTT lowering.

9 September 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FHFrank Herrmann
Frank Herrmann
MHManuela Hessmann
Manuela Hessmann
SSSabine Schaertl
Sabine Schaertl
KBKarola Berg-Rosseburg
Karola Berg-Rosseburg
CBChristopher J. Brown
Christopher J. Brown
JBJonathan A Bard
Jonathan A Bard
Huntington’s disease (HD) is caused by a CAG trinucleotide repeat expansion in the first exon of the huntingtin (HTT) gene coding for the huntingtin (HTT) protein. The misfolding and consequential aggregation of CAG-expanded mutant HTT (mHTT) underpin HD pathology. Our interest in the life cycle of HTT led us to consider the development of high-affinity small-molecule binders of HTT oligomerized/amyloid-containing species that could serve as either cellular and in vivo imaging tools or potential therapeutic agents. We recently reported the development of PET tracers CHDI-180 and CHDI-626 as suitable for imaging mHTT aggregates, and here we present an in-depth pharmacological investigation of their binding characteristics. We have implemented an array of in vitro and ex vivo radiometric binding assays using recombinant HTT, brain homogenate-derived HTT aggregates, and brain sections from mouse HD models and humans post-mortem to investigate binding affinities and selectivity against other pathological proteins from indications such as Alzheimer’s disease and spinocerebellar ataxia 1. Radioligand binding assays and autoradiography studies using brain homogenates and tissue sections from HD mouse models showed that CHDI-180 and CHDI-626 specifically bind mHTT aggregates that accumulate with age and disease progression. Finally, we characterized CHDI-180 and CHDI-626 regarding their off-target selectivity and binding affinity to beta amyloid plaques in brain sections and homogenates from Alzheimer’s disease patients.

5 August 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LLLongbin Liu
Longbin Liu
PJPeter D. Johnson
Peter D. Johnson
MPMichael E. Prime
Michael E. Prime
VKVinod Khetarpal
Vinod Khetarpal
MLMatthew Lee
Matthew Lee
CDCelia Dominguez
Celia Dominguez

22 December 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LLLongbin Liu
Longbin Liu
PJPeter D. Johnson
Peter D. Johnson
MPMichael E. Prime
Michael E. Prime
VKVinod Khetarpal
Vinod Khetarpal
CBChristopher J. Brown
Christopher J. Brown
CDCelia Dominguez
Celia Dominguez

1 January 2002 in Agronomy Journal
Verified
Journal Article
Closed access
PDF file
JBJoshua B. Beam
Joshua B. Beam
DJDavid Jordan
David Jordan
AYAlan C. York
Alan C. York
TIThomas G. Isleib
Thomas G. Isleib
JBJack E. Bailey
Jack E. Bailey
PJP. Dewayne Johnson
P. Dewayne Johnson

1 March 2002 in Agronomy Journal
Verified
Journal Article
Closed access
PDF file
JBJoshua B. Beam
Joshua B. Beam
DJDavid Jordan
David Jordan
AYAlan C. York
Alan C. York
TIThomas G. Isleib
Thomas G. Isleib
JBJack E. Bailey
Jack E. Bailey
PJP. Dewayne Johnson
P. Dewayne Johnson